Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,200.00DKK
22 Feb 2018
Change (% chg)

kr.181.00 (+17.76%)
Prev Close
kr.1,019.00
Open
kr.1,105.00
Day's High
kr.1,213.50
Day's Low
kr.1,104.00
Volume
1,495,641
Avg. Vol
339,528
52-wk High
kr.1,489.00
52-wk Low
kr.994.80

Select another date:

Wed, Feb 21 2018

BRIEF-Genmab ‍2017 Operating Profit Beats Expectations

* ‍PROJECTED REVENUE FOR 2018 CONSISTS PRIMARILY OF DARZALEX ROYALTIES OF APPROXIMATELY DKK 1,750 MLN THAT ARE BASED ON AN ESTIMATED USD 2.0 - 2.3 BLN OF DARZALEX NET SALES IN 2018​

BRIEF-Genmab 2017 Net Sales Of DARZALEX At $1.24 Billion

* ANNOUNCES 2017 NET SALES FIGURES FOR DARZALEX® (DARATUMUMAB)

BRIEF-Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​

* ANNOUNCES NOVARTIS’ INTENTION TO TRANSITION ARZERRA® (OFATUMUMAB) FROM COMMERCIAL AVAILABILITY TO LIMITED AVAILABILITY VIA COMPASSIONATE USE PROGRAMS FOR THE TREATMENT OF CLL IN NON-US MARKETS

BRIEF-U.S. FDA Grants Priority Review For Daratumumab In Front Line Multiple Myeloma

* U.S. FDA GRANTS PRIORITY REVIEW FOR DARATUMUMAB IN FRONT LINE MULTIPLE MYELOMA

BRIEF-Gemnab Says Artisan Partners Increased Indirect Ownership In Co To 5.04 Pct Of Share Capital and Voting Rights

* GENMAB - ‍ARTISAN PARTNERS INCREASED THEIR INDIRECT OWNERSHIP IN CO TO 3,081,731 SHARES, AMOUNTING TO 5.04% OF SHARE CAPITAL, VOTING RIGHTS IN CO

BRIEF-Biotech Genmab sees 2018 expense growth of 40-50 pct

Dec 12 FOLLOWING ARE STATEMENTS FROM GENMAB'S R'N'D UPDATE IN ATLANTA, GEORGIA:

Genmab and Johnson & Johnson 'love' partnership as some ponder takeover

LONDON Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion this year and propelled the Danish antibody specialist to the top spot.

Europe's top biotech expects delays from drugs watchdog's HQ move

LONDON Europe's biggest biotechnology company, Denmark's Genmab, expects some delays to regional drug approvals as the European Medicines Agency is uprooted from London to Amsterdam.

Europe's top biotech expects delays from drugs watchdog's HQ move

LONDON Europe's biggest biotechnology company, Denmark's Genmab, expects some delays to regional drug approvals as the European Medicines Agency is uprooted from London to Amsterdam.

Europe's top biotech expects delays from drugs watchdog's HQ move

LONDON, Nov 30 Europe's biggest biotechnology company, Denmark's Genmab, expects some delays to regional drug approvals as the European Medicines Agency is uprooted from London to Amsterdam.

Select another date: